Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
“The good performance we saw in the third quarter has continued to further improve.
A group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that it will create a monopoly and harm competition.
David Roth, Chief Financial Officer of 4basebio AG, comments: “4basebio can now successfully acquire the desired number of shares in full.
Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59 percent 5-year CAGR of Masthercell under Orgenesis’ leadership
Revolution Medicines snagged $238 million through its initial public offering to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.
Summit Therapeutics plc announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA.
Funding to support GMP adenovirus manufacture for a first-in-human basket clinical trial in melanoma, lung cancer, and triple negative breast cancer
Valeritas and its subsidiaries filed for Chapter 11 bankruptcy on February 9, 2020 in the District of Delaware. At the same time, Zealand entered into the definitive deal to buy the assets.
Founded by UKI2S with co-investment from LifeArc & Parkwalk to advance a diabetic macular edema gene therapy and other pipeline products
Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units at a price of $0.20 per Unit.